Analysts Set Genmab A/S (NASDAQ:GMAB) Target Price at $45.20

Genmab A/S (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $45.20.

GMAB has been the topic of several research reports. Truist Financial decreased their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th.

Institutional Trading of Genmab A/S

Several large investors have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. increased its stake in Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares during the last quarter. Choreo LLC acquired a new stake in Genmab A/S in the second quarter valued at about $776,000. Charles Schwab Investment Management Inc. grew its position in Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after acquiring an additional 12,654 shares during the last quarter. Renaissance Technologies LLC raised its stake in Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Genmab A/S in the third quarter worth about $709,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Genmab A/S stock opened at $20.31 on Friday. The stock has a 50-day simple moving average of $21.80 and a 200 day simple moving average of $24.78. The stock has a market capitalization of $13.44 billion, a P/E ratio of 19.72, a PEG ratio of 0.67 and a beta of 0.96. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the prior year, the firm posted $0.47 earnings per share. Research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.